President Trump recently signed the Right to Try bill, S. 204 (115), allowing terminally ill patients to bypass the Food and Drug Administration (FDA) to request experimental drug treatments. The measure encountered some opposition from lawmakers who were concerned it doesn’t provide enough protections for patients and could undermine the FDA.
Trump, who previously committed to sign the legislation during the State of the Union address, called it a promise he kept to the American people. Despite the name, the legislation grants no real rights to patients, but it allows them an option to get experimental medication from a pharmaceutical company. However, pharmaceutical companies are not mandated to provide the medication.
Read more about the Right to Try legislation here.
